RxDoctor Payments Data

Marit Thorsgard, MD

Interventional Cardiology · Saint Paul, MNNPI 1841436383

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 65.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $2,859 and has fallen 63.6% since, to $1,041 in 2025.

$8,594in general payments, 2019–2025

Across 171 payments — averaging $50.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Medical Device Business Services, Inc.$779
  • Medtronic$762
  • Edwards Lifesciences$740
  • Abbott$197
  • Biotronik Inc.$130
  • plus $332 from 5 others
$3,736in research payments, 2019–2025

Across 1 payment — averaging $3736.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$4K

What the payments were for

  • Travel & lodging$3,99947%
  • Food & beverage$4,58353%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,594 in reported general payments places this provider in the 60th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$83,956
Medicare patients
424
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$106,028
Repatha SureclickEvolocumab42$39,133
BrilintaTicagrelor16$16,250
Metoprolol Succinate227$3,884
Atorvastatin Calcium144$2,632
Rosuvastatin Calcium134$2,629
Losartan Potassium86$1,384
Ezetimibe45$1,203
ClopidogrelClopidogrel Bisulfate76$1,177
Carvedilol79$1,142
Amlodipine Besylate60$663
Dilt-XrDiltiazem Hcl14$519
Lisinopril41$347
Nitroglycerin40$327
Hydrochlorothiazide29$257

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →